DE60314823D1 - Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene - Google Patents

Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene

Info

Publication number
DE60314823D1
DE60314823D1 DE60314823T DE60314823T DE60314823D1 DE 60314823 D1 DE60314823 D1 DE 60314823D1 DE 60314823 T DE60314823 T DE 60314823T DE 60314823 T DE60314823 T DE 60314823T DE 60314823 D1 DE60314823 D1 DE 60314823D1
Authority
DE
Germany
Prior art keywords
virus
vaccination
antigens
neonatal
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60314823T
Other languages
English (en)
Other versions
DE60314823T3 (de
DE60314823T2 (de
Inventor
Paul Chaplin
Mark Suter
Mathias Ackermann
Marco Franchini
Sabine Vollstedt
Hans Peter Hefti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60314823(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of DE60314823D1 publication Critical patent/DE60314823D1/de
Application granted granted Critical
Publication of DE60314823T2 publication Critical patent/DE60314823T2/de
Publication of DE60314823T3 publication Critical patent/DE60314823T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60314823.9T 2002-04-19 2003-04-16 Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene Expired - Lifetime DE60314823T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK200200590 2002-04-19
DKPA200200590 2002-04-19
PCT/EP2003/003994 WO2003088994A2 (en) 2002-04-19 2003-04-16 Modified vaccinia virus ankara for the vaccination of neonates
EP03732280.7A EP1420822B2 (de) 2002-04-19 2003-04-16 Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene

Publications (3)

Publication Number Publication Date
DE60314823D1 true DE60314823D1 (de) 2007-08-23
DE60314823T2 DE60314823T2 (de) 2008-03-13
DE60314823T3 DE60314823T3 (de) 2017-11-16

Family

ID=29225556

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60314823.9T Expired - Lifetime DE60314823T3 (de) 2002-04-19 2003-04-16 Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene

Country Status (24)

Country Link
US (3) US7897156B2 (de)
EP (4) EP1839672A3 (de)
JP (4) JP4801880B2 (de)
KR (2) KR101028937B1 (de)
CN (1) CN100540051C (de)
AT (1) ATE366586T2 (de)
AU (1) AU2003239805B2 (de)
BR (1) BR0309339A (de)
CA (1) CA2478009C (de)
CY (1) CY1106848T1 (de)
DE (1) DE60314823T3 (de)
DK (1) DK1420822T4 (de)
EA (1) EA011233B1 (de)
ES (1) ES2288609T5 (de)
HK (1) HK1078777A1 (de)
IL (1) IL163701A0 (de)
MX (1) MXPA04010353A (de)
NO (1) NO336348B1 (de)
NZ (2) NZ547776A (de)
PL (1) PL220781B1 (de)
PT (1) PT1420822E (de)
SG (1) SG173216A1 (de)
UA (1) UA85371C2 (de)
WO (1) WO2003088994A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676389A (zh) * 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
DE60314823T3 (de) * 2002-04-19 2017-11-16 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
AU2003294248A1 (en) * 2002-11-07 2004-06-03 Aventis Pasteur, Inc. Smallpox vaccine regimen
EP1855720B2 (de) * 2005-02-23 2023-04-26 Bavarian Nordic A/S Verwendung von einem modifizierten pockenvirus für die schnelle induktion von immunität gegen pockenviren oder andere infektiöse stoffe
EP1835031A1 (de) * 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Verwendung eines rekombinanten modifizierten Vaccinia Ankara Virus (MVA) zur Behandlung der Typ-I Hypersensitivität in einem lebenden Tier einschließlich des Menschen
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
EP2303322A1 (de) * 2008-06-20 2011-04-06 Bavarian Nordic A/S Rekombinanter modifizierter vaccinia-virus-masern-impfstoff
WO2012059243A2 (en) * 2010-11-05 2012-05-10 Bavarian Nordic A/S Modulation of immune responses by the poxviral k4 protein
US9821054B2 (en) 2011-03-11 2017-11-21 Turnstone Limited Partnership Method of vaccination comprising a histone deacetylase inhibitor
EP2892549A1 (de) * 2012-09-04 2015-07-15 Bavarian Nordic A/S Verfahren und zusammensetzungen zur verbesserung von impfstoffimmunreaktionen
US9707291B2 (en) * 2013-03-15 2017-07-18 Bavarian Nordic A/S Single high dose of MVA induces a protective immune response in neonates and infants
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
UA113442C2 (xx) 2015-01-27 2017-01-25 Ентеросорбент
EP3297660A2 (de) 2015-05-20 2018-03-28 The Broad Institute Inc. Gemeinsam genutzte neoantigene
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
JP7034080B2 (ja) * 2016-02-25 2022-03-11 メモリアル スローン ケタリング キャンサー センター ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
JOP20210186A1 (ar) 2019-01-10 2023-01-30 Janssen Biotech Inc مستضدات البروستاتا المستحدثة واستخداماتها
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
WO2023118508A1 (en) * 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914408A (en) * 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (de) 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPS6035647A (ja) † 1983-08-09 1985-02-23 Nippon Denso Co Ltd アンチスキツド制御装置
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5403582A (en) 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2188447C (en) 1994-04-29 2002-10-22 Falko-Gunter Falkner Recombinant poxviruses with foreign polynucleotides in essential regions
US5753489A (en) 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AP964A (en) 1996-02-21 2001-05-11 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunisation.
EP0951555A2 (de) * 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Rekombinantes mva-virus das dengue-virus antigene exprimiert und dessen verwendung in impfstoffen
AU5091898A (en) * 1996-10-25 1998-05-15 Wistar Institute Of Anatomy And Biology, The Method of vaccinating infants against infections
US6204250B1 (en) 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO1999007869A1 (en) 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
GB2347932B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Vectors for the delivery of 5T4 antigen
SI1263936T1 (sl) * 2000-03-14 2006-06-30 Bavarian Nordic As Spremenjen sev modificiranega virusa vakcinacije Ankara (MVA)
CA2409874A1 (en) 2000-05-24 2001-11-29 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
EP1292694A2 (de) * 2000-06-15 2003-03-19 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Ein rekombinantes nicht replizierendes gmcsf exprimierendes virus und verwendungen davon zur erhöhung der immunantworten
DE50109630D1 (de) 2000-07-11 2006-06-01 Bayer Healthcare Ag Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP2345665A3 (de) * 2001-12-04 2012-02-15 Bavarian Nordic A/S Impfstoff aus der NS1-Untereinheit eines Flavivirus
DE60314823T3 (de) * 2002-04-19 2017-11-16 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
AU2003236646B2 (en) * 2002-05-16 2009-01-15 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
CA2538193C (en) * 2003-09-10 2011-01-04 Ra Brands, L.L.C. Process for imprinting a composite ventilated rib
EP1694364B1 (de) * 2003-11-12 2014-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services System zur behandlung und prävention von brustkrebs
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
EP1835031A1 (de) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Verwendung eines rekombinanten modifizierten Vaccinia Ankara Virus (MVA) zur Behandlung der Typ-I Hypersensitivität in einem lebenden Tier einschließlich des Menschen
EP1925318A1 (de) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Rekombinanter modifizierter Vaccinia Virus Ankara (MVA)-basierter Impfstoff gegen Vogelgrippe
US8613936B2 (en) * 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements

Also Published As

Publication number Publication date
EP1420822A2 (de) 2004-05-26
CA2478009C (en) 2019-03-26
BR0309339A (pt) 2005-03-08
ES2288609T3 (es) 2008-01-16
JP2015061876A (ja) 2015-04-02
DK1420822T3 (da) 2007-10-08
EP1839672A2 (de) 2007-10-03
HK1078777A1 (en) 2006-03-24
EP1420822B2 (de) 2017-07-05
KR20110017904A (ko) 2011-02-22
US20110135683A1 (en) 2011-06-09
JP4801880B2 (ja) 2011-10-26
PL220781B1 (pl) 2016-01-29
EP1420822B1 (de) 2007-07-11
SG173216A1 (en) 2011-08-29
DE60314823T3 (de) 2017-11-16
EP2204179A3 (de) 2010-12-22
EA200401405A1 (ru) 2005-04-28
IL163701A0 (en) 2005-12-18
US20120183574A1 (en) 2012-07-19
US20090104224A1 (en) 2009-04-23
AU2003239805B2 (en) 2009-09-10
WO2003088994A2 (en) 2003-10-30
NO20044941L (no) 2004-11-12
JP5690214B2 (ja) 2015-03-25
EP2204180A3 (de) 2010-12-22
JP2011157400A (ja) 2011-08-18
US7897156B2 (en) 2011-03-01
ES2288609T5 (es) 2017-11-13
NZ547776A (en) 2009-08-28
PT1420822E (pt) 2007-09-04
WO2003088994A3 (en) 2004-02-19
EP1839672A3 (de) 2007-11-21
CN100540051C (zh) 2009-09-16
AU2003239805A1 (en) 2003-11-03
UA85371C2 (ru) 2009-01-26
CY1106848T1 (el) 2012-05-23
NZ536592A (en) 2007-01-26
DE60314823T2 (de) 2008-03-13
DK1420822T4 (en) 2017-10-09
CA2478009A1 (en) 2003-10-30
CN1646158A (zh) 2005-07-27
MXPA04010353A (es) 2005-03-07
EP2204179A2 (de) 2010-07-07
PL371594A1 (en) 2005-06-27
JP2005523318A (ja) 2005-08-04
KR20040111467A (ko) 2004-12-31
JP2010120955A (ja) 2010-06-03
US8163293B2 (en) 2012-04-24
ATE366586T2 (de) 2007-08-15
EP2204180A2 (de) 2010-07-07
KR101028937B1 (ko) 2011-04-12
NO336348B1 (no) 2015-08-03
EA011233B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
ATE366586T2 (de) Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
Nah et al. The present and future of veterinary vaccines for Japanese encephalitis in Korea
Sautto et al. Next generation vaccines for infectious diseases
Razzuoli et al. The swine IFN system in viral infections: Major advances and translational prospects
Toledo et al. Human αIFN co-formulated with milk derived E2-CSFV protein induce early full protection in vaccinated pigs
Zhang et al. Type III interferon gene expression in response to influenza virus infection in chicken and duck embryonic fibroblasts
Lawson et al. Interleukin-1β expression by a recombinant porcine reproductive and respiratory syndrome virus
Alhaji Saganuwan Protection of SARS-CoV-2 trial vaccines in human is a function of the viral genomes
US20170335345A1 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis c
Medina et al. Recoding the genome of FMDV: A path for the development of live attenuated vaccine (LAV) candidates against FMD
Shen et al. Cytokine mRNA expression in chicken experimentally infected with different avian reovirus strains
Myrzakhmetova et al. Immune reactivity of two biological models to vaccination with inactivated vaccine QazVac against coronavirus infection COVID-19
WO2024049355A1 (en) Mutations that stabilize and attenuate dengue virus genome
KR20150137215A (ko) 신규한 돼지 생식기 호흡기 증후군 바이러스, prrs 예방 또는 치료용 면역원성 조성물, 및 그를 이용하여 prrs를 예방 또는 치료하는 방법
Kannan et al. Evolving trends in molecular virulence, pathogenesis, symptomatology and epidemiology of recent Middle East respiratory syndrome coronavirus (MERS-CoV)
CN112156180A (zh) 预防新型冠状病毒病的疫苗
Abt Commensal bacterial communities regulate antiviral immunity
Kim et al. Human Adenovirus Type 5 as a Delivery Vector is Not Neutralized in Field Serum Samples of Cattle, Pig, and Goat of Republic of Korea
TH58478B (th) รีคอมบิแนนท์ไวรัสของโรคนิวคาสเซิลที่ใช้ทำวัคซีนสำหรับเอมบริโอ
You et al. OL-031 The role of Interleukin-12p70 in dengue virus infection
Mogler et al. A paper to be submitted to Vaccine
RU2333007C3 (ru) Полипептидные вакцины для широкой защиты против рядов поколений менингококков с повышенной вирулентностью
TH75687A (th) วัคซีนไวรัสโรคโลหิตจางในไก่จากเซลล์ไลน์
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)

Legal Events

Date Code Title Description
8363 Opposition against the patent